Allarity Therapeutics (NASDAQ: ALLR) — Perfil da empresa, notícias e dados financeiros
Allarity Therapeutics pioneers personalized cancer treatment through its Drug Response Predictor platform, aiming to enhance patient outcomes.
Allarity Therapeutics
Allarity Therapeutics (NASDAQ:ALLR) focuses on pioneering personalized medicine, primarily by developing drugs that target cancer treatment based on the individual's genetic makeup. The company's approach prioritizes the DRP® platform (Drug Response Predictor), a cutting-edge tool aiming to predict a patient’s response to a specific cancer therapy, thereby enhancing treatment efficacy and minimizing unnecessary exposure to potential side effects. Among its key projects are several promising oncology drugs in various stages of development, each selected for their potential to meet unmet medical needs in cancer care. Allarity’s objective is to revolutionize how cancer is treated, making therapy personal and more effective by aligning treatment strategies with genetic profiles, ultimately improving patient outcomes and quality of life.
Resumo
Operações
Produtos e/ou serviços de Allarity Therapeutics
- Stenoparib, an inhibitor targeting ovarian cancer through PARP inhibition, facilitating DNA damage in cancer cells.
- IXEMPRA® (Ixabepilone), a microtubule inhibitor for the treatment of metastatic breast cancer, offering an alternative in cases resistant to anthracyclines and taxanes.
- LiPlaCis®, a lipid-conjugated form of cisplatin, designed to increase drug delivery to tumors, reducing systemic toxicity, focusing on metastatic breast cancer and prostate cancer.
- 2X-111, a liposome-encapsulated doxorubicin aimed at glioblastoma and metastatic breast cancer, intended to pass through the blood-brain barrier.
equipe executiva do Allarity Therapeutics
- Thomas H. JensenFounder, CEO & Director
- Jeremy R. GraffPresident & Chief Development Officer
- Steen Meier KnudsenFounder & Chief Scientific Officer
- Jeffrey S. ErvinChief Financial Officer
- Jose L. IglesiasConsultant Chief Medical Officer
Últimas notícias sobre a Allarity Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Allarity Therapeutics, em USD.
- Cap. de mercado
- 15,1 mi
- Receita (TTM)
- 345 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 320 mil | -12,6 mi | -11,2 mi | |
| 0 | -27,2 mi | -24,5 mi | |
| 0 | -17,1 mi | -11,9 mi | |
| 0 | -34,5 mi | -16,1 mi |